A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Public ClinicalTrials.gov record NCT01144351. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and tolerability of ELND002 in patients with relapsing forms of secondary progressive multiple sclerosis (SPMS) or relapsing-remitting multiple sclerosis (RRMS).
Study identification
- NCT ID
- NCT01144351
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2010 (Type not available)
- Primary completion
- Dec 2012 (Actual)
- Completion
- Not listed
- Last update posted
- Dec 14, 2015
Started 2010
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Berkeley | California | 94705 | — |
| Research Site | Fresno | California | 93710 | — |
| Research Site | Newport Beach | California | 92663 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Tampa | Florida | 33609 | — |
| Research Site | Vero Beach | Florida | 32960 | — |
| Research Site | Northbrook | Illinois | 60062 | — |
| Research Site | Farmington Hills | Michigan | 48334 | — |
| Research Site | Minneapolis | Minnesota | 55404 | — |
| Research Site | Albuquerque | New Mexico | 87106 | — |
| Research Site | Raleigh | North Carolina | 27607 | — |
| Research Site | Cincinnati | Ohio | 45219 | — |
| Research Site | Uniontown | Ohio | 44685 | — |
| Research Site | Cordova | Tennessee | 78258 | — |
| Research Site | Knoxville | Tennessee | 37920 | — |
| Research Site | San Antonio | Texas | 78258 | — |
| Research Site | Salt Lake City | Utah | 84106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01144351, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 14, 2015 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01144351 live on ClinicalTrials.gov.